All Oncology News

The European Commission has approved nivolumab as a treatment for patients with advanced melanoma in the first- and later-line setting regardless of BRAF mutation status, making it the first PD-1 inhibitor to gain approval in Europe.

Second-line treatment with ramucirumab did not improve overall survival compared with placebo in the full population of patients with advanced hepatocellular carcinoma examined in the phase III REACH study.

Patients with chemorefractory KRAS wild-type metastatic colorectal cancer had a statistically significant improvement in overall survival when treated with panitumumab (Vectibix) versus best supportive care, according to data released from a phase IlI study.

International genome-­wide association study (GWAS) also identifies key gene responsible for expressing subtype of ovarian cancer.

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer.

OncLive® announced an addition to its vibrant Strategic Alliance Partnership program today as VCU Massey Cancer Center signed onto the program's mission to raise awareness of cancer treatment and research.

For insight on the potential of ONT-380 in HER2-positive breast cancer, OncLive spoke with the lead author of the primary phase Ib analysis, Erika P. Hamilton, MD.

The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival by 4.9 months compared with the two agents alone in untreated patients with advanced pancreatic cancer who expressed high-levels of hyaluronan.

The IDH1 inhibitor AG-120 and the IDH2 inhibitor AG-221 have demonstrated promising outcomes in patients with hematologic malignancies, including those with acute myeloid leukemia in two separate phase I clinical trials.

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.

Risk of inflammation and cognitive impairment due to chemotherapy, often called "chemobrain", may be reduced by maintaining physical activity during treatment.

Treatment with inotuzumab ozogamicin demonstrated a complete response (CR) or CR with incomplete platelet recovery rate of 80.7% in patients with relapsed or refractory acute lymphoblastic leukemia.

Many oncology professionals who treat patients on regorafenib are unfamiliar with how to manage and prevent hand-foot skin reaction.

The addition of panobinostat to bortezomib and dexamethasone improved progression-free survival by 7.8 months in a subgroup of 147 patients with multiple myeloma who had received at least 2 prior treatments, including bortezomib and an immunomodulatory agent.

With bipartisan support, legislation aimed at reducing the high copays for self-injectable and oral cancer drugs was introduced in the House and Senate.

Adding liver-direceted Yttrium-90 resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival by 7.9 months for patients with colorectal cancer with liver-dominant metastases.

Adding ofatumumab to fludarabine and cyclophosphamide reduced the risk of disease progression by 54% in patients with relapsed chronic lymphocytic leukemia.

Combination MEK/BRAF inhibition with trametinib and dabrafenib reduced the risk of death by 29% in patients with BRAF-mutant advanced melanoma.

Lead PERSIST-1 author Ruben A. Mesa, MD, deputy director of the Mayo Clinic Cancer Center in Scottsdale, Arizona, discussed the trial's results and pacritinib's potential to change the treatment paradigm for patients with myelofibrosis.

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

Jedd D. Wolchok, MD, discusses the unique design and goals of the CheckMate-067 trial, and what its results mean for patients with advanced melanoma going forward.

Treatment with the PARP inhibitor rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer

Sagar Lonial, MD, discusses the future of monoclonal antibodies in multiple myeloma.

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

The CD19-targeted chimeric antigen receptor T-cell therapy CTL019 demonstrated early evidence of activity and safety in patients with refractory multiple myeloma.

Baylor Research Institute (BRI) at Dallas and the Translational Genomics Research Institute in Phoenix, AZ, today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

The FDA has scheduled an ODAC advisory hearing to discuss the biologics license application for necitumumab in combination with gemcitabine and cisplatin as a first-line treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer.

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced NSCLC across all histologies whose disease has progressed on or after platinum-containing chemotherapy, as well as a targeted agent in EGFR- or ALK-positive patients.

Twelve of the nation's leading oncology physicians, researchers and academicians were recognized by their peers as the 2015 Giants of Cancer Care at a ceremony hosted by OncLive at the Chicago Illuminating Company last night. The awardees included medical pioneers selected by a panel of eminent oncologists for landmark achievements in translational research, gene therapy, immuno-oncology and other groundbreaking work that has changed the course of cancer treatment.